ADL Amdl,

TUSTIN, Calif., June 6 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that the British Journal of Oral and Maxillofacial Surgery in 2005 published a study by Chinese scientists from Wuhan University, China, showing that AMDL's DR-70(R) cancer detection test was effective in screening patients with oral cancer because of its sensitivity in demonstrating increased levels of DR-70(R) in the patients tested and could be of significant value in diagnosing oral cancer. "In certain area of Asia oral cancer accounts for about half of all malignancies," the scientists from the Department of Oral Maxillofacial Surgery, Wuhan University, write. "Early detection of oral cancer involves screening, but most screening requires specialists' examinations, which are costly and time-consuming. A rapid and cheap method for the early detection of carcinoma of the tongue is therefore essential." The study compared DR-70(R) use in 52 patients with carcinoma of the tongue compared with 40 controls and 42 patients with benign lesions in the tongue. The scientists determined that "serum concentrations of AMDL DR-70(R) were significantly higher in patients with malignant disease of the tongue than in control groups. Diagnostic sensitivity of AMDL DR-70(R) was 73 percent and specificity was 93 percent." "No substantial progress has been made in the past two decades in improving earlier diagnosis of oral cancer, the Chinese scientists conclude. "The search for non-invasive ways of diagnosing these cancers," such as AMDL's DR-70(R), "is desirable." "This study is of enormous importance because of the prevalence of oral cancer in China combined with our recent announcements of the purchase of a pharmaceutical company in the world's most populous nation and our efforts to seek approval to market DR-70(R) in that nation," said Gary L. Dreher, AMDL CEO. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO, AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright